 Hoth Therapeutics Inc NASDAQ: HOTH announced proof-of-concept data generated using an Alzheimers disease mouse model, supporting the therapeutic potential of HT-ALZ. HT-ALZ is in development under the 505b2 regulatory pathway for the treatment of dementia-related to Alzheimers disease AD. 